PCP
RMD icon

Perbak Capital Partners’s ResMed RMD Stock Holding History

Perbak Capital Partners’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,140
Closed -$929K – 199
2026
Q1 		$929K Buy
4,140
+2,738
+195% +$682K 0.23% 83
2025
Q4 		$338K Sell
1,402
-1,970
-58% -$504K 0.1% 123
2025
Q3 		$923K Buy
3,372
+1,458
+76% +$398K 0.16% 143
2025
Q2 		$494K Buy
+1,914
New +$457K 0.11% 185
2024
Q3 		– Sell
-2,100
Closed -$402K – 52
2024
Q2 		$402K Buy
+2,100
New +$426K 0.12% 55

Other funds holding RMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Perbak Capital Partners's RMD Position: Q2 2026 in Review

Perbak Capital Partners sold out of ResMed (RMD) in Q2 2026, closing a stake of 4,140 shares — an estimated $929K sold.

Perbak Capital Partners first reported a position in RMD in Q2 2024 and held it in 5 quarters. The position peaked at $929K in Q1 2026. 889 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Perbak Capital Partners reported no remaining ResMed position as of Q2 2026 after selling out during the quarter.
  • Perbak Capital Partners sold 4,140 ResMed shares in Q2 2026, an estimated $929K.
  • Perbak Capital Partners first reported a position in ResMed in Q2 2024 and held it in 5 quarters.
  • Perbak Capital Partners's ResMed position peaked at $929K in Q1 2026.
  • 889 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Perbak Capital Partners's 13F filing for Q2 2026.